WO2003015789A3 - A pharmaceutical composition for dermal application - Google Patents
A pharmaceutical composition for dermal application Download PDFInfo
- Publication number
- WO2003015789A3 WO2003015789A3 PCT/DK2002/000538 DK0200538W WO03015789A3 WO 2003015789 A3 WO2003015789 A3 WO 2003015789A3 DK 0200538 W DK0200538 W DK 0200538W WO 03015789 A3 WO03015789 A3 WO 03015789A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbopol
- active component
- glycol
- pharmaceutical composition
- permulen
- Prior art date
Links
- 230000036576 dermal application Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229920002125 Sokalan® Polymers 0.000 abstract 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 2
- 239000003995 emulsifying agent Substances 0.000 abstract 2
- 210000002615 epidermis Anatomy 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 abstract 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 abstract 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 abstract 1
- 230000002500 effect on skin Effects 0.000 abstract 1
- 229920001519 homopolymer Polymers 0.000 abstract 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
- 230000035515 penetration Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A pharmaceutical composition for dermal application comprising, as an active component, a compound of general formula I And a pharmaceutically acceptable vehicle comprising a solvent for the active component capable of effecting penetration of the active component into the epidermis, and further comprising a polymeric emulsifier which is incapable of penetrating into the epidermis, may be used in the prevention or treatment of dermal inflammatory diseases or conditions such as dermatitis. Polymeric emulsifiers of the type preferably included in the present composition are generally classified as “carborners” but differ from the homopolymeric carbomers by being cross-linked copolymers and are preferably selected from the group consisting of (Permulen® TR1, Permulen ® TR2m carbomer 1342 (NF), ((Carbopol ® 1342, -Carbopol® 1382, Carbopol ® or Carbopol® ETD 2050. The solvent comprises a non-toxic glycol or glycol ether selected from the group consisting of propylene glycol, butylene glycol and ethoxy diglycol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002333193A AU2002333193A1 (en) | 2001-08-15 | 2002-08-15 | A pharmaceutical composition for dermal application |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31209901P | 2001-08-15 | 2001-08-15 | |
| US60/312,099 | 2001-08-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2003015789A2 WO2003015789A2 (en) | 2003-02-27 |
| WO2003015789A3 true WO2003015789A3 (en) | 2004-03-04 |
Family
ID=23209876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/DK2002/000538 WO2003015789A2 (en) | 2001-08-15 | 2002-08-15 | A pharmaceutical composition for dermal application |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2002333193A1 (en) |
| WO (1) | WO2003015789A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2638850T3 (en) | 2013-02-19 | 2017-10-24 | Pfizer Inc. | Azabenzimidazole compounds as inhibitors of PDE4 isoenzymes for the treatment of CNS disorders and other disorders |
| US10131669B2 (en) | 2014-07-24 | 2018-11-20 | Pfizer Inc. | Pyrazolopyrimidine compounds |
| MX376283B (en) | 2014-08-06 | 2025-03-07 | Pfizer | IMIDAZOPYRIDAZINE COMPOUNDS. |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997004795A2 (en) * | 1995-07-25 | 1997-02-13 | Poli Industria Chimica S.P.A. | Pharmaceutical compositions containing cyclosporin or other peptide substances |
| WO1999024041A1 (en) * | 1997-11-10 | 1999-05-20 | Cellegy Pharmaceuticals, Inc. | Penetration enhancing and irritation reducing systems |
| WO2001005744A1 (en) * | 1999-07-16 | 2001-01-25 | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) | Novel aminobenzophenones |
| EP1120417A2 (en) * | 1989-03-23 | 2001-08-01 | SMITHKLINE BEECHAM PHARMA GmbH | Xanthine derivatives for the treatment of cerebrovascular disorders |
-
2002
- 2002-08-15 AU AU2002333193A patent/AU2002333193A1/en not_active Abandoned
- 2002-08-15 WO PCT/DK2002/000538 patent/WO2003015789A2/en not_active Application Discontinuation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1120417A2 (en) * | 1989-03-23 | 2001-08-01 | SMITHKLINE BEECHAM PHARMA GmbH | Xanthine derivatives for the treatment of cerebrovascular disorders |
| WO1997004795A2 (en) * | 1995-07-25 | 1997-02-13 | Poli Industria Chimica S.P.A. | Pharmaceutical compositions containing cyclosporin or other peptide substances |
| WO1999024041A1 (en) * | 1997-11-10 | 1999-05-20 | Cellegy Pharmaceuticals, Inc. | Penetration enhancing and irritation reducing systems |
| WO2001005744A1 (en) * | 1999-07-16 | 2001-01-25 | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) | Novel aminobenzophenones |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002333193A1 (en) | 2003-03-03 |
| WO2003015789A2 (en) | 2003-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1695708A3 (en) | Pharmaceutical composition | |
| WO2004011054A3 (en) | Injectable multimodal polymer depot compositions and uses thereof | |
| US8575108B2 (en) | Cyclosporin compositions | |
| ZA200206553B (en) | Pharmaceutical composition. | |
| BRPI0409185A (en) | topical anthelmintic veterinary formulations | |
| WO2005087195A3 (en) | Novel compositions for topical delivery | |
| WO2003041757A3 (en) | Catheter injectable depot compositions and uses thereof | |
| CA2594215A1 (en) | Sustained-release nanoparticle compositions and methods for using the same | |
| WO2007000778A3 (en) | Modified release pharmaceutical compositions on the basis of two polymers and processes thereof | |
| RU2006136805A (en) | Ivermectin-containing cream gel | |
| WO2005000241A3 (en) | Compositons and methods for topical administration | |
| WO2002019969A3 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
| WO2004080415A3 (en) | Gel composition and method for treatment of vaginal infections | |
| CA2457034A1 (en) | Ophthalmic composition comprising an ascomycin | |
| AU2002361265A1 (en) | Pharmaceutical composition for the treatment of psoriasis and other skin diseases | |
| WO2005037949A3 (en) | Aerosol formulations of butalbital, lorazepam, ipratropium, baclofen, morphine and scopolamine | |
| WO2001085139A3 (en) | Semi-solid delivery vehicle and pharmaceutical compositions | |
| US20050277584A1 (en) | Pharmaceutical compositions comprising cyclosporins | |
| WO2000061068A3 (en) | Anthelmintic compositions | |
| WO2003015789A3 (en) | A pharmaceutical composition for dermal application | |
| EP1320357B1 (en) | Topical polymeric antimicrobial emulsion | |
| WO2004062668A1 (en) | Ophthalmic compositions containing loratadine | |
| EP2018102B1 (en) | Topical insect repellent composition and method of application | |
| WO2005074912A2 (en) | Antiparasitic composition containing an organic amine salt of closantel | |
| WO2022020114A3 (en) | Methods for the prevention and treatment of hearing loss |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |